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a  b  s  t  r  a  c  t
Introduction  and Objectives:  Nonalcoholic-fatty-liver  disease  (NAFLD)  is  considered  the  hepatic  mani-
festation  of metabolic  syndrome  (MetS).  Mineralocorticoid  receptor  (MR)  activation  is  associated  with
increased  risk  of MetS  but few studies  have  assessed  the  role  of  liver  MR on  NAFLD.  We  aimed  to  evaluate
the  effect  of MR  modulation  by sodium  intake  in  liver  injury  in  experimental  models  of NAFLD.
Materials  and  Methods:  C57BL/6J  mice  were  fed  either  a  high-fat-diet  (HFD)  or a  choline/methionine
deficient  (MCD)  diet  with  different  sodium  concentrations.  Hepatic  concentration  of lipid  species,  serum
aldosterone  levels,  expression  of MR,  proinflammatory  and  profibrotic  markers  and  liver  histology  were
assessed.
Results:  Mice  fed  with  High-Na+/HFD  showed  a lower  MR  expression  in  liver  (p  =  0.01)  and  less  steatosis
on  histology  (p =  0.04).  Consistently,  animals  from  this  group  exhibited  lower  levels  of  serum  aldosterone
(p  = 0.028)  and  lower  hepatic  triglyceride  content  (p  =  0.008).  This  associated  to  a  reduced  expression  of
lipogenic  genes,  significant  changes  in lipid  subspecies,  lower  HOMA-IR  (p <  0.05),  and  lower  expression
of  pro-inflammatory  and  profibrotic  markers  compared  to those  mice  fed  a  Low-Na+/HFD.  Additionally,
mice  fed  a High-Na+/HFD  showed  higher  expression  of  salt-inducible  kinase  (SIK)-1  and  lower  expression
of  serum-and-glucocorticoid-inducible  kinase  (SGK)-1.  Similar  results  were  observed  with  the MCD  diet
model.
Conclusion:  We  identified  in  two  experimental  models  of NAFLD  that  High-Na+ diet content  is  associated
to  lower  serum  aldosterone  levels  and  hepatic  MR downregulation,  associated  to decreased  steatosis  and
reduced de novo  hepatic  lipogenesis,  proinflammatory  and  profibrotic  markers.  Decreased  activation  of
hepatic MR  seems  to  generate  beneficial  downstream  inhibition  of  lipogenesis  in  experimental  NAFLD.©  2021  Fundación  Clínica  M
article  under  the  CC
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD), the most com-
mon  liver disease worldwide, is an heterogeneous disorder. The
acronym groups different patient populations with a spectrum
of liver histological abnormalities and different natural history
and prognosis. The term non-alcoholic steatohepatitis (NASH)
is applied when inflammation and evidence of hepatocellular
injury (indicated by the presence of hepatocellular ballooning) are
present. Of note, NASH is considered the more aggressive form of
the disease that conveys a worse prognosis [1]. In the last decade,
NAFLD became the focus of intense research due to the pandemic
proportions it has reached (affecting almost a quarter of the world’s
population) [2,3]. Furthermore, NAFLD has been recognized as an
independent risk factor for cardiovascular disease and type 2 dia-
betes mellitus (T2DM) as well as for some cancers [4–7].
Broadly, its pathogenesis is conceived as a sequential process
where steatosis (pathological intracellular accumulation of lipids
in the form of triglycerides) develops first, followed by local inflam-
mation and triggering of a stereotyped fibrotic response to injury
that contributes to progression to advanced liver fibrosis and
cirrhosis [8]. Metabolic dysfunction reflected in the presence of
metabolic syndrome (MetS) and insulin-resistance (IR) are con-
sidered central for NAFLD development and progression [2,9,10].
However, multiple pathophysiological pathways are involved and
it is likely that they contribute differently in a given patient [11].
Dietary factors can contribute to steatosis development and
eventually to disease progression [12]. Saturated fats and carbohy-
drates, particularly fructose, stimulate hepatic de novo lipogenesis,
being associated with increased hepatic lipid content, inflamma-
tion, and possibly fibrosis [13]. Nutritional evaluation of patients
with NAFLD had shown that they follow a western diet with a high
content of fat and sodium and a suboptimal intake of micronu-
trients [14]. High sodium has been associated with increased
glucocorticoids production, IR, pro-inflammatory cytokines and
MetS in humans [15]. In obese mice, dietary sodium regulates
the expression of adiponectin and sodium restriction reduces the
profile of proinflammatory adipokines [16]. Another relevant pro-
tein regulated by sodium intake is the mineralocorticoid receptor
(MR). The MR,  normally activated by aldosterone and modulated
by sodium intake, is expressed mainly in kidneys and heart [17].
MR activation is associated with fibrosis in target organs and also
promotes inflammation, cardiovascular dysfunction, and adipose
tissue differentiation [18]. Interestingly, MR  blockade with specific
antagonists like spironolactone or eplerenone ameliorated fibroge-
nesis in heart and kidney [19,20]. Liver MR  is involved in hepatic
fibrogenesis [21], which is potentially relevant for NAFLD progres-
sion. Previous work have shown that local activation of MR  induces
hepatocellular injury [22] and MR  blockade with spironolactone or
eplerenone decreased liver fibrosis in experimental models [21].
However, data on how sodium modulates hepatic MR  expression
is scarce [17,23].
Changes in sodium intake can modulate MR levels, pro-
inflammatory cytokines and adiponectin in obese mice [16,17,23].
Also, chronic high sodium intake has been linked to MetS and
NAFLD beyond the well-known effect in hypertension [15,24].
Shorter modifications of sodium with restricted intake can increase
acutely aldosterone levels and be associated, counterintuitively, to
metabolic dysregulation [25] and IR. Studying how sodium intake,
MR activation and other factors that modulate liver damage is
important because it can help identify potential therapeutic tar-
gets and long-term new approaches/treatments for clinical use
[26]. In this work, we assess the effect over MR  expression and
NAFLD development by modulating sodium intake in two dietetic
NAFLD mice models, focusing the activation of lipogenesis and lipid
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ffect in the HFD-fed mice model which is a more physiological
odel that mimics the feeding behavior observed in western pop-
lations. And second, we  will perform our experimental approach
sing the MCD-fed mice which reproduce the most important hall-
arks in NAFLD to NASH progression like hepatic inflammatory
nfiltration but lacking the extrahepatic features observed in most
AFLD individuals like obesity and insulin resistance.
. Material and methods
.1. Animals and diet
Male mice of 10 weeks (C57BL/6J, Jackson Laboratories, Bar
arbor, Maine) were used in accordance with protocols estab-
ished by the ethical committee of our institution. Each animal
as kept in an individual polycarbonate cage with controlled light
nd temperature. At the beginning of the study all animals were
ed with a standard diet (Prolab 3000, Purina, PMI  Feeds Inc.,
t. Louis MO). Two dietetics models were used to study NAFLD
rogression: High-fat diet (HFD) with 60% of calories provided
y fat (#D12492, Research diets Inc., New Brunswick, NJ) for 12
eeks; and methionine-choline deficient (MCD) diet with 60 kcal%
at (# A06071302, Research diets Inc., New Brunswick, NJ) for 6
eeks. Sodium concentration was  modified in each diet obtain-
ng: (0.3%) (Normo-Na+), high sodium (3%) (High-Na+) and low
odium content (0.03%) (Low-Na+) [27]. Mice were grouped (n = 10)
s follow: High-Na+/HFD, Normo-Na+/HFD, Low-Na+/HFD, High-
a+/MCD, Low-Na+/MCD. The results were compared to a control
roup consisting of mice fed with chow diet that with standard
odium content (0.3%). Mice that did not respond to HFD in terms
f weight gaining were excluded from the study. Mice were euth-
nized through bleeding under generalized anesthesia. Samples
rom serum, liver, kidney, muscles and adipose tissue were taken
nd flash frozen to -80 ◦C until further analysis.
.2. Laboratory parameters
Alanine aminotransferase levels (ALT) was  measured using a
ovalent kit (Rio de Janeiro, Brazil) and results were expressed
s IU/L. Serum triglyceride was  measured through commercial
its (Sigma, St. Louis, MO). Adiponectin was  measured through
LISA (QuantikineTM R&D Systems, Minneapolis, MN). Aldosterone
as measured through Alpha Diagnostic International ELISA (San
ntonio, Texas). Glycemia and insulin levels were measured with
uman kits (Wiesbaden, Germany). HOMA-IR (Homeostasis Model
ssessment-Insulin resistance) was  calculated with the formula
asting glycemia mg/dL × fasting insulin level ng/mL/22.5. Hep-
tic triglycerides were measured through the Folch method from
.5 mL  of homogenized liver tissue mixed with CHCl3-CH3OH (2:1,
/v).
.3. Histologic analysis
Liver sections from the right lobe of all mouse livers were rou-
inely fixed in 10% formalin and embedded in paraffin. Then 4 m
issue sections were stained with hematoxylin/eosin and Sirius-red
taining. Nuclei were counterstained with Hematoxylin. A blind
nvestigator assigned a score for steatosis and inflammation as
escribed [28]. Scores were given as it follows: Steatosis: grade 0,
one present; grade 1, steatosis of <25% of parenchyma; grade 2,
teatosis of 26–50% of parenchyma; grade 3, steatosis of 51–75% of
arenchyma; grade 4, steatosis of >76% of parenchyma and inflam-
ation: grade 0, no inflammatory foci; grade 1, 1–5 inflammatory
oci per high power field; grade 2, >5 inflammatory foci/high power
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Fig. 1. Effect of High fat diet (HFD) with different Na+ content on anthropometric parameters and metabolic markers on mice. A) High-Na+/HFD induced less weight gain
compared to Normo-Na+/HFD and Low-Na+/HFD. B) There were no significant differences in plasma alanine aminotransferase (ALT) levels between HFD with different Na+































Na+/HFD. E) Representative images from histologic samples stained with H&E show
of  steatosis per field. G) High-Na+/HFD induced less hepatic triglyceride expression
ANOVA.
field. Liver fibrosis was quantified using digital image analysis of the
red-stained area in Sirius red stained samples (ImageJ, NIH, USA).
2.4. Real-time PCR
Total RNA from hepatic tissue was isolated using Speed Vac-
uum Total RNA Isolation System (Promega Corporation, Madison,
WI,  USA). Then it was quantified with a Nanodrop ND-1000 spec-
trophotometer. Reverse transcription (RT) was performed using
1 ug of total RNA, Quantitative Real Time PCR (qRT-PCR) was
carried out in a StepOnePlusTM (96-well) PCR System (Applied
Biosystems, Thermofisher, Waltham, MA,  USA) using SYBR Green
method. The sequences of the primer sets are described in the
Supplementary materials file. mRNA levels were normalized to
the housekeeping gene 18S and further normalized to the mean
expression level of the control group. Relative gene expression was
calculated via the 2 ddct. The genes studied are described in Suppl.
Table 1.
2.5. Lipid content
For analysis of liver lipid concentration, lipids were extracted
by the method described by Folch et al. [29] and then, they were
separated by thin layer chromatography as described by Ruiz &
Ochoa [30]. Free fatty acid and triglyceride levels were determined
using commercial Kits (Menarini Diagnostics, Italy) from hepatic
homogenate and lipid extract, respectively. Liver concentration of
diglycerides, different species of cholesterol and glycerophospho-
lipids were determined using a GS-800 densitometer and Quantity
One software (Bio Rad, USA).
2.6. Statistical analysisAll results are expressed as mean with standard deviation.
Two tailed non-paired student t-test was used to compare results






at High-Na+/HFD induced less hepatic steatosis than Low-Na+/HFD. F) Percentage
ormo-Na+/HFD and Low-Na+/HFD. n = 10 mice per group, *p < 0.05, ** p < 0.01 by
sed to compare 2 or more groups. Significant p-value ≤0.05.
NOVA was used for comparison parametric variables between
ultiple groups. Post-hoc analysis using Bonferroni or Dunn was
sed to correct for multiple comparisons. Histologic variables were
xpressed as percentages and Chi-Square test was  used to compare
roups. All data were analyzed and graphed with GraphPad 8 Prism
GraphPad Software, Inc).
. Results
.1. Effect of HFD with different sodium content on liver steatosis
nd IR
We used a HFD mice model of NAFLD, which in spite of being
 mild-intensity model most closely mimics the pathophysiol-
gy of human NAFLD with IR and MetS [31]. Fig. 1 shows the
nthropometric and serum parameters after 12 week of experi-
ental diet feeding. HFD-fed mice had a larger increase in body
eight (p < 0,001), the High-Na+/HFD group had a slightly lower
ncrease in body weight by the end of the experiment (Fig. 1A),
espite consuming the same amount of food. The plasma levels
f ALT were similar between the groups, only significant differ-
nces were found between the chow-fed group (55.5 ± 2.4 IU/L)
nd the Low-Na+/HFD group (141.1 ± 19 IU/L), (p = 0.01) (Fig. 1B).
asting glycemia was higher in the groups with Normo-Na+/HFD
153.5 ± 8.6 mg/dL) and Low-Na+/HFD (142.5 ± 8.5 mg/dL), com-
ared to the High-Na+/HFD group (103.3 ± 6.9 mg/dL, p = 0.008
ith respect to Normo-Na+/HFD) and chow (83.75 ± 3.9 mg/dL)
Fig. 1C). Insulin levels showed a similar pattern, with a significant
ncrease in the Low-Na+/HFD group (2.1 ± 0.26 ng/mL) com-
ared to the High-Na+/HFD group (1.2 ± 0.3 ng/mL, p = 0.04) and
how (0.87 ± 0.12 ng/mL, p = 0.02) (Fig. 1C). Consistently, HOMA-
R was significantly higher in the Normo-Na+/HFD (11.4 ± 1.7)
nd Low-Na+/HFD (13.95 ± 2.5) groups compared to the High-
a+/HFD (4.44 ± 0.59, p < 0.05) and chow (3.2 ± 0.57, p < 0.05)
roups (Fig. 1C). On the other hand, plasma adiponectin levels, an
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Next, we assessed hepatic expression of selected inflamma-
tion and fibrosis-related genes to better evaluate the impact of theHigh-Na+/HFD induced less percentage of steatosis than Low-Na+/HFD measured u
fibrosis between HFD with different Na+ content using Sirius Red staining 40×.  n = 
adipokine that upregulates lipid oxidation and catabolism, were
lower in the High-Na+/HFD group (4.52 ± 0.03 g/mL) compared
to mice fed Normo-Na+/HFD (4.69 ± 0.02 g/mL, p = 0.003) and
chow (4.7 ± 0.04 g/mL, p = 0.03) (Fig. 1D). To assess the impact
of our intervention on liver histology, we assessed liver tissue for
steatosis and fibrosis. Evaluation of the liver parenchyma with
H&E staining showed a higher percentage of liver steatosis in
the Low-Na+/HFD group (50.5 ± 9.2%) compared to the High-
Na+/HFD group (18.3 ± 7.59%, p = 0.04) and chow (0%, p = 0.01)
(Fig. 1E and F). Evaluation of hepatic triglyceride content con-
firmed histology findings. Mice fed High-Na+/HFD had a lower
hepatic triglyceride content (67.38 ± 7.85 mg/g of liver) com-
pared to Normo-Na+/HFD (107.3 ± 5.56 mg/g of liver), p = 0.04)
and Low-Na+/HFD groups (117.4 ± 8.57 mg/g of liver, p = 0.008).
In addition, as expected, the lowest amount of liver triglyc-
erides (38.73 ± 3.75 mg/g of liver) was observed in the chow
group, not being different from the High-Na+/HFD group (Fig. 1G).
This finding was confirmed by evaluating histological sections by
staining Oil-red-O, where the High-Na+/HFD group showed signif-
icantly lower liver steatosis (24.9%) than Low-Na+/HFD (62.4%) or
Normo-Na+/HFD (37.7%) (Fig. 2A). No differences in fibrosis were
observed by Sirius-red staining (5.5% in the High-Na+/HFD vs. 5.8%
in the Low-Na+/HFD group) (Fig. 2B). In summary, we  demon-
strated that mice fed with High-Na+/HFD developed less steatosis,
MetS and IR, compared to Normo-Na+/HFD and Low-Na+/HFD
groups. d
4
Oil-Red-O Staining 40×.  B) There were no significant differences in percentage of
e per group, *p < 0.05, by ANOVA.
.2. Effect of HFD with different content of sodium on serum
ldosterone levels and hepatic mineralocorticoid receptor
xpression
We  hypothesize that secondary to chronic High-Na + exposure
educes aldosterone availability and hepatic MR is downregu-
ated.Serum aldosterone levels were lower in High-Na+/HFD-fed
ice (554.3 ± 27.28 pg/mL) compared to Low-Na+/HFD-fed mice
671.4 ± 21.93 pg/mL, p = 0.028) and chow (695 ± 2.69 pg/mL,
 = 0.007) (Fig. 3A). This suggests that in our model aldosterone is
ainly regulated by sodium intake, independent of lipid ingestion.
ssessment of mRNA expression of MR  in liver samples, showed
hat the group fed with High-Na+/HFD had a lower relative expres-
ion with respect to the groups fed with Normo-Na+/HFD (p ≤ 0.01)
nd Low-Na+/HFD (p ≤ 0.01) (Fig. 3B). In contrast, the expression of
R in the kidney showed no differences between the experimental
roups (p = 0.32) (Fig. 3C). This suggests that MR expression in the
idney is regulated differently and that there is a local modulation
f serum aldosterone levels and MR  expression in the liver.
.3. Effect of HFD with different content of sodium in markers of
nflammation and fibrosisietary sodium changes in the HFD model of steatohepatitis. Low-
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Fig. 3. Down-modulation of the mineralocorticoid pathway by High-Na+/HFD in the liver. A) High-Na+/HFD showed less serum aldosterone level than Low-Na+/HFD. B)
High-Na+/HFD induced less hepatic MR  expression than Normo-Na+/HFD and Low-Na+/HFD. C) There was no significant difference in kidney MR expression between HFD
 than Low-Na+/HFD. E) High-Na+/HFD induced less serum MCP-1 expression than Low-
FD. G) High-Na+/HFD induced MMP9  expression than Low-Na+/HFD. H) High-Na+/HFD
p < 0.01, ***p < 0.001.
Fig. 4. Effect of HFD with different Na+ content of lipid species. A) High-
Na+/HFD induces less content of neutral lipids (triglycerides, diglycerides and
fatty acids) determined by chromatography. B) High-Na+/HFD induces signifi-
cantly less content of cholesterol ester but no difference in free cholesterol. C)
High-Na+/HFD does not induce less content of glycerophospholipids (phosphatidyl-
choline, phosphatidylethanolamine, lysophosphatidylcholine, phosphatidylserine,






with  different Na+ content. D) High-Na+/HFD induced less serum TNF-a expression
Na+/HFD. F) High-Na+/HFD induced less serum TIMP-1 expression than Low-Na+/H
induced MMP13 expression than Low-Na+/HFD n = 10 mice per group, *p < 0.05, ** 
Na+/HFD -fed mice exhibited a higher TNF- mRNA hepatic mRNA
levels were significantly higher than the other experimental groups
(Fig. 3E). Regarding fibrosis, we tested the levels of TIMP-1, which
were decreased in mice fed with high sodium (Fig. 3F). While the
levels of MMP9 and MMP13 were found augmented (Fig. 3G and H).
These findings, suggest that, in the presence of steatosis, changes
in sodium intake modulates inflammation and fibrosis.
3.4. Effect of HFD with different content of sodium in liver lipids
sub-species and lipogenesis
In order to assess if sodium intake modulates liver lipid
species accumulating during steatosis, we extracted liver lipids
by chromatography and quantified them with optic densitom-
etry. We  observed significant differences in the liver content
of neutral lipids with diglycerides being higher in Low-
Na+/HFD-fed mice (201.6 ± 11.07 nmol/mg protein) compared
to Normo-Na+/HFD-fed mice (148.5 ± 11.37 nmol/mg protein,
p = 0.003) and High-Na+/HFD-fed (100.6 ± 5.36 nmol/mg pro-
tein, p < 0.0001) and chow (63.75 ± 3.64 nmol/mg protein,
p < 0.0001) (Fig. 4A). Hepatic triglycerides content was  higher in
the mice under Low-Na+/HFD-fed (372.4 ± 20.33 nmol/mg pro-
tein) and Normo-Na+/HFD-fed (347.7 ± 20.11 nmol/mg protein),
compared to High-Na+/HFD-fed mice (190.6 ± 18.42 nmol/mg
protein, p < 0.0001) and chow (119.8 ± 3.4 nmol/mg pro-
tein, p < 0.0001)) (Fig. 4A). Total liver non-esterified fatty acid
concentration (NEFA) was lower in the group of mice fed High-
Na+/HFD (139.4 ± 8.9 nmol/mg protein), compared to mice fed
Normo-Na+/HFD (199.9 ± 7.1 nmol/mg protein, p = 0.0003) and
Low-Na+/HFD (199.1 ± 9.9 nmol/mg protein, p = 0.0004) and higher
than the chow group (100.8 ± 3.7 nmol/mg protein, p = 0.045))
(Fig. 4A). Regarding sterols, not changes were observed in free
cholesterol, but hepatic cholesterol ester content was higher
in mice under Low-Na+/HFD (18.32 ± 0.89 nmol/mg protein),
compared to mice fed Normo-Na+/HFD (12.68 ± 0.88 nmol/mg
protein, p = 0.0009), High-Na+/HFD (10.17 ± 0.93 nmol/mg
protein, p < 0.0001) and chow (4.85 ± 0.25 nmol/mg pro-
tein, p < 0.0001) (Fig. 4B). With regard to glycerophospho-
lipids (phosphatidylcholine, phosphatidylethanolamine, lysophos-
phatidylcholine, phosphatidylserine, phosphatidylinositol, and
cardiolipin) no differences were observed (Fig. 4C) across the






ipogenic enzymes, with the exception of SREBP1. n = 10 mice per group, *p < 0.05,
*  p < 0.01, ***p < 0.001 by ANOVA.
ontent in mice fed High-Na+/HFD (13.63 ± 0.51 nmol/mg protein),
ompared to mice fed Low-Na+/HFD (9.68 ± 0.9 nmol/mg protein,
 = 0.003) (Fig. 4C).
Assessment of the mRNA expression of key hepatic lipogenic
nzymes was carried out in samples from different experimental
roups in order to explore if dietary sodium intake modulates lipid
iosynthesis in liver tissue. Expression of Acetyl-CoA carboxylase
ACC), Fatty acid synthase enzyme (FAS) and Stearoyl-CoA desat-
D. Cabrera, I. Rao, F. Raasch et al. Annals of Hepatology 24 (2021) 100357
































of  how MR activation modifies hepatic lipogenesis. A) High-Na+/HFD induced more
expression than Low-Na+/HFD and Normo-Na+/HFD. C) High-Na+/HFD induced les
than  Low-Na+/HFD. n = 10 mice per group, *p < 0.05, **p < 0.01 by ANOVA.
urase 1 (SCD1) was lower in mice fed High-Na+/HFD (0.68 ± 0.11)
compared to mice fed Low-Na+/HFD (Fig. 4D) suggesting that in
the context of steatosis, dietary sodium modulates lipogenesis in
agreement with previous observations [32]. No differences were
observed when evaluating mRNA levels Sterol regulatory element-
binding protein 1 (SREBP1) (p = 0.68) (Fig. 4D).
3.5. Effect of HFD with different sodium content of on
salt-inducible kinases (SIK) and
serum-and-glucocorticoid-inducible kinase 1 (SGK1) enzymes
Aiming to gain insights on the mechanisms by which the
sodium/aldosterone/MR axis could influence hepatic lipogenesis,
we next explored if sodium content of HFD modulates the hep-
atic expression of salt-inducible kinases (SIKs). In our model, SIK1
expression was significantly lower in’ groups of mice fed with
HFD compared to chow (Fig. 5A). Of note, SIK1 expression was
significantly higher in mice fed with High-Na+/HFD compared to
Low-Na+/HFD and Normo-Na+/HFD (Fig. 5B). This suggests that
SIK1 expression is regulated by lipid content and sodium content
of diet. The expression of SIK2 was significantly lower in High-
Na+/HFD compared to Low-Na+/HFD (Fig. 5C). Finally, we assessed
the hepatic expression of the enzyme serum-and-glucocorticoid-
inducible kinase 1 (SGK1), observing a downregulation of SGK1
with High-Na+/HFD and an upregulation with Low-Na+/HFD
(Fig. 5D).
3.6. Effect of high and low sodium content in MCD-induced
steatohepatitis
Finally, we used the MCD  diet for 6 weeks as a second
NAFLD/NASH mouse model to explore the effects of modulation
of MR by dietary sodium on liver damage; this model of NASH
is not associated with significant IR but associated with inflam-
mation and fibrosis. We  used Mice fed MCD  diet did not show






 expression than low and Normo-Na+/HFD. B) High-Na+/HFD induced more SIK-1
2 expression than Low-Na+/HFD. D) High-Na+/HFD induced less SGK1 expression
ial weight, at the end of 6 weeks between the High-Na+/MCD
88.92 ± 1.77%) and Low-Na+/MCD (91.55 ± 4.0%, p = 0.79) (Fig. 6A).
n the other hand, liver mass was  lower in the group fed High-
a+/MCD (1.14 ± 0.04 g) compared to the group fed Low-Na+/MCD
1.52 ± 0.05 g, p < 0.0001) (Fig. 6A). Of note, hepatic triglyc-
ride content in mice fed High-Na+/MCD was significantly lower
han that of mice fed a Low-Na+/MCD ((24.83 ± 1.8 mg/g liver vs.
3.25 ± 2.3 mg/g of liver, p < 0.0001) (Fig. 6B) similar to that we
bserved in animals fed HFD with different sodium contents. In
he MCD  fed-mice. Additionally, HOMA was similar between these
wo groups (p = 0.37) (Fig. 6C). To assess inflammation, MCP-1
issue expression was evaluated showing no statistically signif-
cant difference between the group of mice fed High-Na+/MCD
0.87 ± 0.06) and those fed Low-Na+/MCD (0.90 ± 0.1, p = 0.86)
Fig. 6D). Unlike what was  observed with the HFD diet, fibrosis
arkers TIMP1 and -SMA expression did not show differences
etween groups (Fig. 6D). Regarding lipogenesis, it was observed
hat the expression of Fatty acid synthase (FAS) was  lower in mice
ed High-Na+/MCD (1.1 ± 0.3) compared to mice fed Low-Na+/MCD
2.6 ± 0.36, p = 0.0005), without evidencing statistical difference in
he other enzymes involved in lipogenesis (Fig. 6E). As expected,
lasma aldosterone levels were lower in the group of mice fed
igh-Na+/MCD (925.3 ± 28.5 pg/mL) compared to mice fed Low-
a+/MCD (1076 ± 36.36 pg/mL, p = 0.011) (Fig. 6F). Additionally, MR
xpression in both liver and kidney was significantly lower in mice
ed High-Na+/MCD compared to Low-Na+/MCD-fed mice (Fig. 6F).
. Discussion
We  studied the effect of MR  modulation by sodium intake on
iver injury in 2 different experimental models of NAFLD and made
everal novel observations: 1) mice fed with High-Na+/HFD devel-
ped less steatosis, MetS and IR than the comparison groups; 2)
2 week administration of a High-Na+/HFD consistently decreased
epatic aldosterone and MR  expression levels 3) Lower MR expres-
ion was associated with less steatosis, inflammation and fibrosis
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Fig. 6. Effect of MCD  with high and low Na+ concentration on hepatic steatosis and activation of mineralocorticoid receptor signaling. A) There was no significant difference
in  increase of weight in mice fed with MCD, however, there is significantly less liver weight gain in the High-Na+/MCD. B) High-Na+/MCD showed less percentage of hepatic
triglycerides content than Low-Na+/MCD. C) There were not significant differences in HOMA-IR calculated between the different MCD  groups. D) There were no significant
differences between different MCD  groups in expression of fibrosis markers including monocyte chemoattractant protein-1, tissue inhibitor of metalloproteinases-1, alpha
smooth muscle actin. E) There were not significant differences between different MCD  groups in lipid genes activation such as ACC, SREBP1, SCD1. There is significantly
less  expression of FAS in High-Na+/MCD compared to Low-Na+/MCD. F) High-Na+/MCD activates mineralocorticoid receptor signaling significantly less than Low-Na+/MCD,
with  less serum aldosterone level, hepatic mineralocorticoid receptor (MR) activation and kidney MR activation. n = 10 mice per group, *p < 0.05, ** p < 0.01, ***p < 0.001 by
ANOVA.  G) Summary of the proposed mechanism. We  propose that a high-Na+ intake leads to lower levels of MR  expression, lower levels of aldosterone and less activation



















of  lipogenic enzymes -such as FAS, ACC, SCD1-downstream of SREBP1, resulting in l
or  low-Na+ intake, a HFD induces higher levels of aldosterone, activating the mine
accumulates in the cytoplasm and doesn’t take part in the regulation of hepatic lipo
markers; 4) variation in sodium content of HFD was  associated
with significant changes in hepatic lipidic profile and modulated
the expression of enzymes involved in hepatic lipogenesis; and 5)
SIK1 and SGK1 were modulated by sodium content of HFD, which
could be related to changes in hepatic lipogenesis. Most of the
changes observed in the classic HFD-induced NAFLD mouse model
were recapitulated in mice with MCD-induced NASH. Collectively,
our data suggest that sodium/aldosterone/MR pathway could play
a role in modulating NAFLD development and progression.
We identified that hepatic MR  modulation, rather than the
dietary sodium content by itself, may  regulate the development
and severity of NAFLD in mice. We  observed that High-Na+/HFD-
fed mice expressed lower levels of aldosterone (implying less RAAS
activation) and subsequently lower hepatic MR  levels, they also
displayed lower levels of glycemia, insulinemia and, therefore,
HOMA-IR, compared to Low-Na+/HFD-fed mice. Interestingly, MR
kidney expression was not affected, which could be explained by




ogenesis, therefore less steatosis. Meanwhile, in the livers of animals with normal
rticoid pathway, therefore, causing SIK-1 phosphorylation, phosphorylated SIK-1
 gene expression.
he lower expression of hepatic MR  is a critical finding, since
e recently described that an increased expression of MR  in a
urine NAFLD model is associated with increased inflammation
nd fibrosis and MR  blockade with eplerenone has anti-steatotic
nd anti-fibrotic liver effects [21].Therefore, the High-Na+/HFD
ould have a similar effect than MR antagonists and this could
xplain the reduced steatosis observed in these models. In Low-
a+/HFD-fed mice, there was an induction of a state of secondary
yperaldosteronism and, therefore, an increase in the hepatic
R expression with the pro-steatotic, pro-inflammatory and pro-
brotic effects. Hepatic MR  activation is associated with more
nflammation and fibrosis because RAAS activation has shown to
ause liver damage through vasoactive and profibrotic prolifera-
ion [33]. Furthermore, MR blockage has shown to decrease adipose
nflammation, decrease hepatic collagen deposition, and improve
lucose metabolism [19].
These hypotheses are consistent with histological findings,
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evidencing significant differences in fibrosis based on the Sirius
Red stain finding. This could be explained because the experimental
model of NAFLD with HFD diet does not induce significant fibrosis
[34]. On the other hand, when analyzing gene expression, it is evi-
dent that the group of mice fed with a High-Na+/HFD compared
to the group of mice fed with a Low-Na+/HFD have lower levels of
inflammation (TNF-  and MCP1) and fibrosis markers (TIMP1).
To better characterize the observed changes in steatosis, we
set out to study liver lipogenesis pathways. We  observed a lower
expression of the main enzymes involved in lipogenesis (ACC, SCD1
and FAS) in High-Na+/HFD fed mice compared to the Low-Na+/HFD
group. We did not observe differences in SREBP1, which could be
determined by the short half-life of the mRNA of this transcrip-
tion factor, however, its downstream enzymes (FAS, SCD1) were
consistently modified [35].
Additionally, we evaluated lipids subtypes, observing a
decreased triglyceride content in the group fed with High-Na+/HFD,
this group also showed lower content of cholesterol esters and
higher content of phosphatidylinositol compared to mice fed a
Low-Na+/HFD. Mice fed a High-Na+/HFD had a lower content
of diglycerides. This finding is key since diglycerides are asso-
ciated with hepatic IR [36]. It should be noted that mice under
High-Na+/HFD had a comparatively lower percentage of weight
gain than mice in the Normo-Na+/HFD and Low-Na+/HFD groups,
despite ingesting similar amounts of food. This has been previ-
ously described as a consequence of the effect of salt content on
digestive efficiency [37]. High-Na + intake reduces the total food
intake and appetite, therefore decreasing total body fat and the
development of MetS and NAFLD [38]. Moreover, high-Na + diets
have shown to decrease the storage of lipids within adipocytes by
inhibiting adipocyte differentiation through upregulation of cal-
cium pathways [38]. It is also interesting that the group of mice
with a High-Na+/HFD shows slightly lower levels of adiponectin
[16].
The MCD  diet model of NAFLD constitutes a lean model of liver
injury in which IR and MetS are not present [39] (41), unlike the
HFD model. Consistent with the pathogenesis of the model, there
were no significant differences in HOMA-IR or body weight. How-
ever, differences were observed in the liver mass, being lower
in the High-Na+/MCD-fed mice, Similar to the HFD diet model,
MCD  showed lower levels of aldosterone in High-Na+/MCD-fed
mice. In addition, lower hepatic triglyceride content and decrease
in FAS were observed. No differences were observed in the pro-
inflammatory and pro-fibrotic genes evaluated, probably due to the
early nature of the experimental model (6 weeks).
We  investigated downstream signaling, identifying the family
of salt-inducible kinases (SIK1, SIK2 and SGK1) 26 that play a reg-
ulatory role in steroidogenesis [40,41], modulate inflammation,
participate in cellular processes such as apoptosis and prolifera-
tion and have a role in multiple organs like adipose tissue, heart
and kidney. In particular, SIK1 has shown to modulate lipogen-
esis through regulation of SREBP-1 [32]. Overexpression of SIK1
inhibits liver lipogenic genes expression and SIK-1 knockout mice
greatly increases lipogenic genes expression [32], we observed
that SIK1 expression was significantly higher in mice fed with
High-Na+/HFD compared to Low-Na+/HFD and Normo-Na+/HFD.
On the other hand, SIK2 has shown to inhibits the expression of
lipogenic genes in adipocytes [42]. The expression of SIK2 was
significantly lower in High-Na+/HFD compared to Low-Na+/HFD.
SIK2 has shown to regulates fatty acid oxidation, in the liver,
skeletal muscle, and adipocytes [41].The expression of SGK1 is
upregulated by several types of cell stress, it up-regulates Na+/K+-
ATPase, amino-acid transporters, and several glucose carriers such
as Na + coupled glucose transporter SGLT1. Thus, SGK1 supports cel-
lular glucose uptake and glycolysis, angiogenesis, cell survival, cell
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as a downregulation of SGK1 in mice fed with High-Na+/HFD and
n upregulation in those fed with Low-Na+/HFD.
It is important to note that in our experimental setting we  did
ot potentiate fructose consumption by adding it into the drink-
ng water. High fructose intake per se has been shown to induce
AFLD activating hepatic lipogenesis and inducing insulin resis-
ance. Likewise, a report from Lanaspa et al. [45] showed that
igh salt consumption induced leptin resistance and obesity—and
n consequence NAFLD—in a mechanism mediated by fructose
etabolism. However, this experimental setting differs substan-
ially since the source of sodium was high fructose, high salt in
rinking water and the mechanisms related to feeding behavior
re not the same as drinking. Interestingly, this is not the only
eport showing a paradoxical beneficial effect of high salt intake.
ui et al. showed that total fat mass and especially abdominal fat
ass was decreased in mice fed with a high salt diet [38]. The
roposed mechanisms behind involve the renin-angiotensin sys-
em, calcium signaling, and the participation of CREB1. However,
he involvement of SIK1 and 2 was not addressed. In this way, our
esults suggest novel mechanisms insights to be addressed in fur-
her investigations. We show that high salt intake not only reduces
teatosis in a setting where obesity and insulin resistance plays a
entral role as observed in the data obtained from HFD fed mice. But
lso in an experimental setting where these pathological features
re virtually absent how occurs in the MCD  mice model, suggest-
ng that the mechanisms behind acts in an independent way. HFD
nd MCD  mice model although different share the histological hall-
arks observed in NAFLD patients and this is important because not
ll NAFLD patients are obese. Hence, our results could be extrapo-
ated to the phenotype observed in lean NASH [46]. In the Fig. 6G,
e summarized the results obtained and we proposed a plausible
echanism.
The main limitation of this study is the duration of the treatment
robably representing an acute change in MR  rather than chronic
egarding high-Na + intake. It is anticipated that a long-term model
ill modify RAAS and MR  levels differently. Additionally, these
ndings did not allow us to attribute causality and it was  only eval-
ated for prevention and not for reversion of steatosis. However,
hese results warrant more studies to assess sodium and hepatic
R modulation. The clinical implications of our findings are not
o promote a high-Na + diet but to encourage the potential use of
R antagonists early in the disease and the identification of down-
tream targets such as SIK1, SIK2 or SGK1. In conclusion, this study
dentified in two  experimental models of NAFLD that MR  inactiva-




lna conjugated linoleic acid
A fatty acids
AS Fatty acid synthase
FD high fat diet
OMA-IR Homeostasis Model Assessment-Insulin resistance
R insulin resistance
PC lysophosphatidylcholine
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SCD1 Stearoyl-CoA desaturase 1
SGK1 serum-and-glucocorticoid-inducible kinase
SIK Salt-inducible kinase
SREBP1 Sterol regulatory element-binding protein 1
TIMP1 Tissue inhibitor of Metalloproteinase 1
TNF-a Tumoral necrosis factor-alpha
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